Cell Culture Automation and Quality Engineering: A Necessary Partnership to Develop Optimized Manufacturing Processes for Cell-Based Therapies
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The translation of experimental cell-based therapies to volume produced commercially successful clinical products that satisfy the regulator requires the development of automated manufacturing processes to achieve capable and scaleable processes that are both economic and able to meet the unpredictable demands of the market place. The Healthcare Engineering group at Loughborough has conducted novel demonstrators of the transfer of manual human cell culture processes to the CompacT SelecT (The Automation Partnership) automated cell culture platform, including an osteoblast cell line, embryonic carcinoma cell line, primary bone marrow-derived mesenchymal stem cells, primary umbilical cord-derived progenitor cells, and human embryonic stem cells. The work aims to develop and optimize automated cell culture processes for manufacturing cell-based therapies in a quality system and current good manufacturing practice (cGMP) compliant manner and is underpinned by the application of a six-sigma inspired quality engineering approach. In this technical brief, we outline the need for automated cell culture systems and automated process engineering for the manufacture of cell populations for therapeutic applications. We review the transfer of a manual cell culture process to an automated process and the subsequent methodology for process improvement using examples from our laboratory of the application of these principles to an important regenerative medicine cell type, the human mesenchymal stem cell. We believe that systematic process improvement methodologies combined with the process stability provided by automation are essential to engineer optimized cGMP compliant manufacturing processes that will be required to realize the promise of cell-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why tissue engineering needs process engineering
Archer, R., & Williams, D. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1105-1353 · Cited by 101 · cited 1×
“This transformation is driving an increasing need for robust manufacturing systems for cell-based products to assist the economic and practical feasibility of making emerging therapies by a current good manufacturing practice (cGMP) compliant, a regulated production process.(1,2) Automated cell culture will necessaril…”
BackgroundSelf-citation
Cited by
Long-term maintenance of human induced pluripotent stem cells by automated cell culture system
Konagaya, S., Ando, T., Yamauchi, T., Suemori, H., & Iwata, H. (2015) · Scientific Reports · doi:10.1038/srep16647 · Cited by 94
Harrison, R. P., Ruck, S., Medcalf, N., & Rafiq, Q. A. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.005 · Cited by 72
“Thus, automation of the key unit operations has been identified as a key facilitator of any DCM opportunities [11].”
BackgroundCrombie, D. E., Daniszewski, M., Liang, H. H., Kulkarni, T., Li, F., Lidgerwood, G. E., Conquest, A., Hernández, D., Hung, S. S., Gill, K. P., et al. (2017) · SLAS Discovery · doi:10.1177/2472555217696797 · Cited by 46
“(1) cabinet with medium bottle and pump; (2) carriers for tubes; (3) LiHa wash station; (4) carrier for 5 mL DiTis; (5) waste; (6) carrier for tip boxes; (7) tilting carrier; (8) microplate carrier; (9) transfer station to the Liconic incubator; (10) hotel; (11) carousel, (12) incubator; (13) autoclaved water bottles;…”
BackgroundMethodInfluentialNeedle to needle robot‐assisted manufacture of cell therapy products
Ochs, J., Hanga, M. P., Shaw, G., Duffy, N., Kulik, M., Tissin, N., Reibert, D., Biermann, F., Moutsatsou, P., Ratnayake, S., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10387 · Cited by 18
Metadata
- Authors
- Thomas, R. J., Chandra, A., Hourd, P. C., & Williams, D. J.
- Venue
- JALA: Journal of the Association for Laboratory Automation
- Publisher
- SAGE Publications
- Published
- 2008-06
- Volume
- 13
- Issue
- 3
- Pages
- 152-158
- ISSN
- 1535-5535 (ISSN-L)
- OpenAlex
- W2145460058
- Cited by
- 30
- References
- 1
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.